Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson DARZALEX (daratumumab) by Year
DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%) (%)
Johnson & Johnson DARZALEX (daratumumab): 22.0% in FY2025, down 0.2 pts from a year earlier. That is the lowest of the 8 years on record here.
Where the FY2025 figure comes from
“|| WW | 14,351 | 11,670 | 23.0 | 22.0 | 1.0”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 22.0% | -0.2 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 22.2% | -0.7 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | 22.9% | -16.6 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | 39.5% | -2.8 pts | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
| FY2021 | Jan 2, 2022 | 42.3% | +2.0 pts | Form 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗ |
| FY2020 | Jan 3, 2021 | 40.3% | -11.9 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | 52.2% | -10.2 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | 62.4% | – | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
Breakdown
What makes up DARZALEX (daratumumab)
Cite this data
StockData. (2026). Johnson & Johnson DARZALEX (daratumumab) (%), annual FY2018–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-darzalex-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.